TRML β€” TOURMALINE BIO I

Ownership history in MARSHALL WACE, LLP  Β·  7 quarters on record

This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in TOURMALINE BIO I (TRML). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.01% (2025 Q3)
πŸ“Š Avg. % of fund
0.0%
πŸ“… First filed
2023 Q4
πŸ“… Last filed
2025 Q3
⏱ Quarters held
7
% of Fund (quarterly)
πŸ“‹ Quarterly Holdings History 7 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 143,731 +44,565 +44.9% 0.01% $6.9M β€”
2025 Q1 REDUCED 99,166 -16,925 -14.6% 0.00% $1.5M β€”
2024 Q4 REDUCED 116,091 -22,103 -16.0% 0.00% $2.4M β€”
2024 Q3 REDUCED 138,194 -32,253 -18.9% 0.00% $3.6M β€”
2024 Q2 ADDED 170,447 +31,029 +22.3% 0.00% $2.2M β€”
2024 Q1 ADDED 139,418 +94,422 +209.8% 0.00% $3.2M β€”
2023 Q4 INITIATED 44,996 β€” β€” 0.00% $1.2M β€”

🏒 Other funds also holding TRML

As of 2025 Q3 β€” sorted by position size

Qiming U.S. Ventures Management, LLC 3Y 63.76% PFIZER INC 13.91% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 13.27% QVT Financial LP 3Y 7Y 7.27% Chicago Capital Management, LLC 3Y 7Y 4.81% TCG Crossover Management, LLC 3Y 3.09% Vivo Capital, LLC 3Y 7Y 2.28% HARVEST MANAGEMENT LLC 3Y 7Y 2.07% Versor Investments LP 3Y 7Y 1.91% NEXPOINT ASSET MANAGEMENT, L.P. 3Y 1.89%
← Back to MARSHALL WACE, LLP Holdings